| 000 | 00882 a2200241 4500 | ||
|---|---|---|---|
| 005 | 20250518000114.0 | ||
| 264 | 0 | _c20190813 | |
| 008 | 201908s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/01.wnl.0000544324.09014.0e _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAvasarala, Jagannadha | |
| 245 | 0 | 0 |
_aReader response: Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. _h[electronic resource] |
| 260 |
_bNeurology _c09 2018 |
||
| 300 |
_a580 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Comment | ||
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMultiple Sclerosis, Relapsing-Remitting |
| 773 | 0 |
_tNeurology _gvol. 91 _gno. 12 _gp. 580 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/01.wnl.0000544324.09014.0e _zAvailable from publisher's website |
| 999 |
_c28844514 _d28844514 |
||